This review addresses the ongoing challenges in asthma management, particularly focusing
on patient adherence to inhaler therapy. Asthma, a chronic condition characterized by …

Background Adherence barriers to asthma biologics may not be uniform across
administration settings for patients with moderate-to-severe asthma. Objective To examine …

Background Little is known about adherence to asthma biologics. Research Question Is
adherence to inhaled corticosteroid (ICS) associated with subsequent asthma biologic …

Background Omalizumab therapy was found to be safe and effective as an add-on therapy
for patients with poorly controlled severe asthma. Although several studies over the last …

BACKGROUND: Transthyretin amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed,
life-threatening condition that mostly affects older persons. In May 2019, regulatory approval …

Objective To assess patient-and physician-reported reasons for discontinuing biologic
therapy among patients with severe asthma from a real-world US cohort. Methods This …

Abstract Key points: Between January 2005 and January 2023, the average selling price of
omalizumab increased by nearly 60%. Between 2016 and 2021, Medicare Part B and D …

Background Severe asthma is a serious condition with a significant burden on patients'
morbidity, mortality, and quality of life. Some biological therapies targeting the IgE and …

Background Patient adherence to biologic therapies is crucial for clinical benefits. Previous
assessments of US patient adherence to severe asthma (SA) biologic therapies have relied …

Background In the USA, over 25 million people have asthma; 5%–10% of cases are severe.
Mepolizumab (Nucala) is an interleukin-5 antagonist monoclonal antibody; it was approved …